Colorectal Cancer Market Report and Forecast 2025-2034

Colorectal Cancer Market Overview

Colorectal cancer develops in the tissues of the colon or rectum, located at the lower end of the digestive tract. It is estimated that 1 in 24 individuals are likely to develop the disease in their lifetime. Although counted as one of the most treatable diseases when caught in the early stages, colorectal cancer is considered the leading cause of cancer-related deaths in men. The rising incidence of colorectal cancer along with the increasing aging population is one of the primary factors contributing to the market growth. Increased regular screening programs and advancements in imaging techniques are also supporting the market expansion. Moreover, the rising introduction of targeted therapies, the shift towards combination therapies, and the growth in clinical trials evaluating new treatment options are poised to influence the market dynamics.

Colorectal Cancer Market Growth Drivers

Increasing Prevalence of Colorectal Cancer is Driving Market Growth

According to the American Cancer Society (ACS), around 152,810 new cases of colorectal cancer are estimated to occur in 2024 in the United States, out of which 81,540 cases are predicted to be of men and 71,270 cases will account for women. Further, colorectal cancer is reported as the second-leading cause of all cancer-related deaths in the country and is estimated to be responsible for 53,010 deaths. This increasing burden of colorectal cancer as a result of the growing aging populations and unhealthy lifestyle patterns is expected to fuel market growth.

Colorectal Cancer Market Trends

Colorectal Cancer Market Segmentation

Colorectal Cancer Market Share

Market Segmentation Based on Cancer Type Represents Significant Market Share

The market segmentation by cancer type includes colorectal cancer adenocarcinoma and gastrointestinal carcinoid tumors, among others. Adenocarcinoma accounts for the majority of cases of colorectal cancer, originating in the glandular cells lining the inside of the colon and rectum. Early-stage adenocarcinoma is usually treated with surgery, but combination treatments are often needed to manage advanced cases. The rising availability of targeted therapies like bevacizumab (Avastin) and cetuximab (Erbitux) and immunotherapies like pembrolizumab (Keytruda) is projected to support the growth of this segment in the forecast period.

Colorectal Cancer Market Analysis by Region

The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States dominates the market share owing to the high incidence rate of colorectal cancer which drives the demand for screening, diagnostics, and therapies. The easy availability of advanced treatments including immunotherapies, targeted therapies, and advanced surgical techniques also supports the market growth. Moreover, increasing investments in clinical research and trials along with rising cancer screening initiatives are anticipated to propel the market expansion in the country.

Leading Players in the Colorectal Cancer Market

The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

AstraZeneca

AstraZeneca, headquartered in Cambridge, United Kingdom, is a global, science-led biopharmaceutical business that is actively involved in developing immunotherapy drugs and targeted therapies for various cancers. Its drug candidate AZD-9592 is under clinical development and currently undergoing Phase I trial for metastatic colorectal cancer.

Pfizer, Inc.

Pfizer is one of the leading players in the market with a strong presence in the oncology sector. It...

Novartis AG

Swiss multinational pharmaceutical company Novartis is focused on the development of targeted therap...

Amgen Inc.

Amgen, headquartered in Thousand Oaks, California, has a dominant presence in the market and is well...

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Other key players in the market include F. Hoffmann-La Roche Ltd., GSK plc, Eli Lilly and Company, AbbVie Inc., and Teva Pharmaceuticals Ltd.

Key Questions Answered in the Colorectal Cancer Market Report

• What was the colorectal cancer market value in 2024?
• What is the colorectal cancer market forecast outlook for 2025-2034?
• What are the regional markets covered in the EMR report?
• What is market segmentation based on treatment type?
• What is the market breakup based on cancer type?
• Who are the major end users in the market?
• What are the major factors aiding the colorectal cancer market demand?
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• How do the prevalence and incidence of colorectal cancer affect the market landscape?
• What are the major colorectal cancer market trends?
• How does the expansion of treatment options impact the market size?
• Which treatment type will dominate the market share?
• Which cancer type is expected to have a high market value in the coming years?
• Which end user is projected to contribute to the highest market growth?
• Who are the key players involved in the colorectal cancer market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?